Sector ratings Exelixis, Inc.

Equities

Market Closed - Nasdaq Other stock markets 02:30:00 17/01/2026 am IST			5-day change	1st Jan Change
43.96 ^USD	-3.26%		-0.18%	+0.30%

14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
13/01	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
EXELIXIS, INC.	1.18TCr		BB
ARGENX SE	4.92TCr		AA
WUXI APPTEC CO., LTD.	4.46TCr		AAA
INSMED INCORPORATED	3.44TCr	-	BBB	-		-
BIONTECH SE	2.74TCr	-	-	-		-
WUXI BIOLOGICS (CAYMAN) INC.	2.11TCr		AAA
GENMAB A/S	2.09TCr		AA
AKESO, INC.	1.43TCr		B			-
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	1.42TCr	-	A	-		-
SUMMIT THERAPEUTICS INC.	1.31TCr	-	-	-		-
MYOKARDIA, INC.	1.2TCr	-	-	-	-	-	-	-
SAMSUNG EPIS HOLDINGS CO., LTD.	1.1TCr	-	-	-	-	-	-	-
MADRIGAL PHARMACEUTICALS, INC.	1.14TCr	-	B	-		-
ACCELERON PHARMA INC.	1.09TCr	-	-	-	-	-	-	-
ARROWHEAD PHARMACEUTICALS, INC.	877.35Cr	-	BBB	-		-
NUVALENT, INC.	809.65Cr	-	CCC	-		-
CEREVEL THERAPEUTICS HOLDINGS, INC.	819.15Cr	-	-	-	-	-	-	-
REMEGEN CO., LTD.	798.4Cr		-			-
CYTOKINETICS, INCORPORATED	765.13Cr	-	AA	-		-
METSERA, INC.	742.9Cr	-	B	-	-	-	-
Average	1.72TCr		A
Weighted average by Cap.			A